As of November 8, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of MAIA Biotechnology, Inc. The largest reported stake is Vlad Vitoc's, at 9.66%. 3 filings are on record since December 4, 2025 (Schedule 13D/A, December 4, 2025).
Sell to companies like MAIA Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Solas Capital Management, LLC · Sole voting: 0 · Shared voting: 3,030,845 · Sole dispositive: 0 · Shared dispositive: 3,030,845 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Solas Capital Management, LLC · Percent: 7.1% · SCHEDULE 13G
- · Holder: Vlad Vitoc · Percent: 9.66% · SCHEDULE 13D/A
MAIA Biotechnology, Inc. has 3 Schedule 13D or 13G filings on record since 2025-12-04. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.66% | 3,846,352 | SCHEDULE 13D/A, 2025-12-04 | 2025-11-21 | |
| Solas Capital Management, LLC | 4.9% | 3,030,845 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind MAIA Biotechnology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on MAIA Biotechnology, Inc. and the records around it.
MAIA Biotechnology, Inc. elsewhere on the record
- Company profile and every filing Jan 2026
- Form D filing Jan 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Solas Capital Management, LLC also filed stake reports on 5 other companies: FENNEC PHARMACEUTICALS INC. (Aug 2026), Modular Medical, Inc. (Aug 2026), SANUWAVE Health, Inc. (Aug 2026)
Watch MAIA Biotechnology, Inc.
Get an email when MAIA Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MAIA Biotechnology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MAIA Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MAIA Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Solas Capital Management, LLC | 0 | 3,030,845 | 0 | 3,030,845 | SCHEDULE 13G/A, 2026-08-14 |
| Frederick Tucker Golden | 0 | 3,030,845 | 0 | 3,030,845 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies MAIA Biotechnology, Inc. by CUSIP 552641102 and gives its principal executive office as 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL 60606 (SCHEDULE 13G/A, 2026-08-14).
Purpose of Transaction (Item 4)
Vlad Vitoc
The Reporting Person acquired the Common Stock reported in this Statement for investment purposes. The Reporting Person may in the future acquire additional Common Stock or dispose of some or all of the Common Stock held by the Reporting Person in open-market transactions or privately negotiated transactions, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person may engage in short selling or hedging or similar transactions with respect to the Common Stock, on such terms and at such times as the Reporting Person may deem advisable, subject to applicable law. The Reporting Person has no present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right in the future to formulate any such plans or proposals, and to take any actions with respect to their investments in the Company, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2025-12-04
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-04 | Vlad Vitoc | 9.66% | SCHEDULE 13D/A |
| 2026-05-15 | Solas Capital Management, LLC | 7.1% | SCHEDULE 13G |
| 2026-08-14 | Solas Capital Management, LLC | 4.9% | SCHEDULE 13G/A |
Questions about who owns MAIA Biotechnology, Inc.
Who owns MAIA Biotechnology, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of MAIA Biotechnology, Inc.: Vlad Vitoc (9.66%, Schedule 13D/A, filed 2025-12-04).
When did Vlad Vitoc buy into MAIA Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vlad Vitoc on this page is the Schedule 13D/A, filed 2025-12-04, reporting 9.66%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for MAIA Biotechnology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 5, 2026 | Form D, private offering | $1.51M sold | Form D page | Source |
| October 14, 2025 | Form D, private offering | $2.99M sold | Form D page | Source |
| June 11, 2025 | Form D, private offering | $695K sold | Form D page | Source |
| March 4, 2025 | Form D, private offering | $4.14M sold | Form D page | Source |
| November 12, 2024 | Form D, private offering | $2.44M sold | Form D page | Source |
MAIA Biotechnology, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for MAIA Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.